Kyowa Hakko has participated in the International Society of Sports Nutrition (ISSN) Conference, according to a press release, highlighting products IMMUSE and EYEMUSE.

IMMUSE isLactococcus lactisstrain plasma (LC-plasma), discovered by Kyowa Hakko’s parent company Kirin Holding Company. It acts by activating plasmacytoid dendritic cells (pDC), which in turn activate NK, Killer-T, Helper-T, and B cells, providing immune support. IMMUSE is backed by two safety studies and nine efficacy studies.

Dr. Shintaro Ichikawa, Director of Technical Affairs at Kyowa Hakko USA, said in the press release: “It is well known that prolonged high intensity exercise decreases immune function and increases the risk of upper respiratory tract infections (URTI). It is a serious problem for athletes because not only are URTIs unpleasant, they will also reduce training efficiency. There is emerging evidence that has shown oral intake of LC-Plasma activates pDC and provides immune support. This novel approach to enhance the immune system may improve the experience of continuous high intensity training.”

Related: NBA Basketball Players Found to Have Low O3I Levels Kyowa Hakko Launches “Breathe” Campaign The Active Nutrition Opportunity

EYEMUSE debuted at ISSN. It is a heat-treated paraprobiotic,Lacticaseibacillus paracasei KW3110, which has been shown to support healthy eye function by stimulating the immune cells that produce regulatory cytokines such as IL-10, which may help reduce digital stress-related eye fatigue.

Interested in active nutrition? The Naturally Informed eventActive Nutrition: Mastering the Markettook place June 29-30. If you missed it, no worries—it’ll be available on demand in the first week of July. Register